Boston Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Lawrence MA United States (2009)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2011
NCT02060916
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Boston Therapeutics | Sugardown Company Limited

Active Ingredients

Drugs in Phase 2 Trials (2)

bti320 (2 trials)

paz320 (2 trials)

Drugs in Phase 1 Trials (1)

Key: Boston Therapeutics (0) Acquired (1)

human proislet peptide (2 trials)

Drugs in Other Trials (3)

galactomannans (2 trials)

oryza sativa (1 trial)

sorbitol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Glucose Intolerance (Phase 2)

Hyperglycemia (Phase 2)

Prediabetic State (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 6